Shantha Biotechnics to establish insulin manufacturing facilityIllustrative image – not actual.

Shantha Biotechnics, a subsidiary of French pharmaceutical company Sanofi, is establishing an insulin manufacturing plant in Telangana.


The plant will be set up at a cost of Rs 460 crore and is projected to be in operation by 2019. The project will come up in Gajwel in the neighbouring Medak district. This unit will manufacture Insuman, a human insulin product from the portfolio of Sanofi’s diabetes treatments. This makes it the second Insuman manufacturing plant in the world for Sanofi.


Chief minister, K Chandrasekhar Rao, today laid the foundation stone for the plant. In this unit, the insulin will be manufactured in cartridges. The facility has a capacity to ramp up manufacturing volumes to 60 million cartridges a year in two to three years of commercial manufacturing. Sanofi India launched Insuman cartridges in 2011.


Sanofi’s new facility is targeted at the growing Type 2 diabetes in India, which is home to an estimated 65 million diabetic cases out of the 382 million cases globally. The number in India is expected to touch 109 million by 2035. The plant will meet both, the local and international demand.

 

More Project Info:
Insulin (Gajwel) Project

← All latest storiesBack to top →